

Supplemental Table 3.2d. Transition Probabilities for Eligible Cohort From 10 Through 12 Months. Supplemental Table 3.2d Caption: Transition probabilities for the 8 potential states in the Markov model, as measured among all eligible individuals in the retrospective CD cohort.

| Tx in Month 10 | Tx at the End of 12 Months | | | | | | | | | |
|-------------------|-----------------------------------|-------|----------------------------|---------------------------|--------------------------|----------------------|---------------------|----------------------|----------------------|---------------------|
| | Count Row Percent 95% CI | Total | lost to Fu p | 0: No Meds | 1: CS | 2: IFX | 3: ADA | 4: CTZ | 5: IFX + CS | 6: ADA + CS |
| 0: no meds | 4240 | 232 | 3124 77.9 76.6s-79.2 | 710 17.7 16.5-18.9 | 59 1.5 1.1-1.9 | 22 0.5 0.3-0.8 | 4 0.1 0.0-0.3 | 15 0.4 0.2-0.6 | 8 0.2 0.1-0.4 | 1 0.0 0.0-0.1 |
| 1: CS | 2226 | 71 | 810 37.6 35.5-39.7 | 1247 57.9 55.7-60.0 | 24 1.1 0.7-1.7 | 10 0.5 0.2-0.9 | 4 0.2 0.1-0.5 | 18 0.8 0.5-1.3 | 10 0.5 0.2-0.9 | 1 0.0 0.0-0.3 |
| 2: IFX | 778 | 29 | 73 9.7 7.7-12.1 | 13 1.7 0.9-2.9 | 585 78.1 75.0-81.0 | 5 0.7 0.2-1.6 | 0 0.0 0.0-0.5 | 55 7.3 5.6-9.5 | 4 0.5 0.1-1.4 | 0 0.0 0.0-0.5 |
| 3: ADA | 326 | 1 | 26 8.0 | 2 0.6 | 0 0.0 | 261 80.3 | 4 1.2 | 1 0.3 | 26 8.0 | 0 0.0 |

| Tx in Month 10 | Tx at the End of 12 Months | | | | | | | | | |
|-----------------------------------|----------------------------|-------------------|-----------------------|-----------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Count Row Percent 95% CI | Total | lost to Follow-up | 0: No Meds | 1: CS | 2: IFX | 3: ADA | 4: CTZ | 5: IFX + CS | 6: ADA + CS | 7: CTZ + CS |
| | | | 5.3-11.5 | 0.1-2.2 | 0.0-1.1 | 75.6-84.5 | 0.3-3.1 | 0.0-1.7 | 5.3-11.5 | 0.0-1.1 |
| 4: CTZ | 62 | 1 | 4 6.6 1.8-15.9 | 1 1.6 0.0-8.8 | 0 0.0 0.0-5.9 | 0 0.0 0.0-5.9 | 47 77.0 64.5-86.8 | 0 0.0 0.0-5.9 | 1 1.6 0.0-8.8 | 7 11.5 4.7-22.2 |
| 5: IFX + CS | 185 | 11 | 13 7.5 4.0-12.4 | 16 9.2 5.3-14.5 | 79 45.4 37.9-53.1 | 2 1.1 0.1-4.1 | 1 0.6 0.0-3.2 | 62 35.6 28.5-43.2 | 0 0.0 0.0-2.1 | 0 0.0 0.0-2.1 |
| 6: ADA + CS | 62 | 0 | 9 14.5 6.9-25.8 | 1 1.6 0.0-8.7 | 0 0.0 0.0-5.8 | 32 51.6 38.6-64.5 | 0 0.0 0.0-5.8 | 0 0.0 0.0-5.8 | 16 25.8 15.5-38.5 | 1 1.6 0.0-8.7 |
| 7: CTZ + CS | 26 | 0 | 0 0.0 0.0-13.2 | 3 11.5 2.4-30.2 | 0 0.0 0.0-13.2 | 1 3.8 0.1-19.6 | 6 23.1 9.0-43.6 | 0 0.0 0.0-13.2 | 1 3.8 0.1-19.6 | 13 50.0 29.9-70.1 |

ADA = Adalimumab; CS = corticosteroids; CTZ = Certolizumab; IFX = Infliximab; Tx = treatment. Gray shading denotes no change. Green shading denotes the most common transition when other than no change.